# Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

> **NCT03735225** · PHASE1 · COMPLETED · sponsor: **Zealand Pharma** · enrollment: 60 (actual)

## Conditions studied

- Hypoglycemia

## Interventions

- **DRUG:** Dasiglucagon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03735225
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-07
- **Primary completion:** 2019-06-24
- **Final completion:** 2019-06-24
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03735225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03735225, "Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03735225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*